Advances in the therapy of gastroenteropancreatic-neuroendocrine tumours (GEP-NETs)

Clinical and Translational Oncology

Volumn 12, Issue 7, 2010, Pages 481-492

  Grande, Enrique ^a   Díez, Juan José ^a   Pachón, Vanessa ^a   Carrato, Alfredo ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Angiogenesis; Carcinoid; Everolimus; MTOR pathway; NETs; Neuroendocrine tumours; Pancreatic islet cell carcinoma; Somatostatin analogues; Sunitinib; Treatment

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; BEVACIZUMAB; BIM 23 A 760; CAPECITABINE; CARBOPLATIN; CISPLATIN; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; OCTREOTIDE; PACLITAXEL; PASIREOTIDE; PAZOPANIB; PEGINTERFERON ALPHA2B; PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; SOMATOSTATIN DERIVATIVE; SORAFENIB; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; CARCINOID; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL TUMOR; GENE EXPRESSION; GENE FUNCTION; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; INCIDENCE; MOLECULAR BIOLOGY; MONOTHERAPY; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; PANCREAS TUMOR; PROGRESSION FREE SURVIVAL; REVIEW; SIDE EFFECT; STANDARDIZATION; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MODELS, BIOLOGICAL; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; SOMATOSTATIN; STOMACH NEOPLASMS;

EID: 77956049398     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-010-0541-5     Document Type: Review

References (112)

1. I.M. Modlin K. Oberg D.C. Chung, et al. 2008 Gastroenteropancreatic neuroendocrine tumours Lancet Oncol 9 61 72 10.1016/S1470-2045(07)70410-2 1:CAS:528:DC%2BD1cXivVOltQ%3D%3D 18177818
2. I.M. Modlin K.D. Lye M. Kidd 2003 A 5-decade analysis of 13,715 carcinoid tumors Cancer 97 934 959 10.1002/cncr.11105 12569593
3. S. Oberndorfer 1907 Karcinoide Tumoren des Dünndarms Frank Z Pathol 1 426 432
4. I.M. Modlin M. Kidd R. Pfragner, et al. 2006 The functional characterization of normal and neoplastic human enterochromaffin cells J Clin Endocrinol Metab 91 2340 2348 10.1210/jc.2006-0110 1:CAS:528: DC%2BD28XlvVCgt74%3D 16537680
5. J.C. Yao M. Hassan A. Phan, et al. 2008 One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States J Clin Oncol 26 3063 3072 10.1200/JCO.2007.15.4377 18565894
6. D.L. Reidy L.H. Tang L.B. Saltz 2009 Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors Nat Clin Pract Oncol 6 143 152 10.1038/ncponc1326 1:CAS:528:DC%2BD1MXisVSnsrs%3D 19190591
7. P. Tomassetti M. Migliori S. Lalli, et al. 2001 Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours Ann Oncol 12 [Suppl2] 95 99 10.1023/A:1012468409003
8. O. Hauso B.I. Gustafsson M. Kidd, et al. 2008 Neuroendocrine tumor epidemiology: contrasting Norway and North America Cancer 113 2655 2664 10.1002/cncr.23883 18853416
9. K. Hemminki X. Li 2001 Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden Cancer 92 2204 2210 10.1002/1097-0142(20011015)92:8<2204::AID-CNCR1564>3.0.CO;2-R 1:STN:280:DC%2BD3MrkvVKlsg%3D%3D 11596039
10. C. Lepage B. Rachet M.P. Coleman 2007 Survival from malignant digestive endocrine tumors in England and Wales: a population-based study Gastroenterology 132 899 904 10.1053/j.gastro.2007.01.006 17383419
11. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G et al (2010) Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE) Ann Oncol. doi: 10.1093/annonc/mdq022
12. D.C. Metz R.T. Jensen 2008 Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors Gastroenterology 135 1469 1492 10.1053/j.gastro. 2008.05.047 1:CAS:528:DC%2BD1cXhsVOhtb3K 18703061
13. C. Capella P.U. Heitz H. Höfler, et al. 1995 Revised classification of neuroendocrine tumours of the lung, pancreas and gut Virchows Arch 425 547 560 10.1007/BF00199342 1:STN:280:DyaK2M3htFaqtg%3D%3D 7697211
14. U.F. Pape H. Jann J. Müller-Nordhorn, et al. 2008 Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors Cancer 113 256 265 10.1002/cncr.23549 18506737
15. G. Klöppel A. Perren P.U. Heitz 2004 The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification Ann N Y Acad Sci 1014 13 27 10.1196/annals.1294.002 15153416
16. G. Klöppel G. Rindi A. Perren, et al. 2010 The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement Virchows Arch 456 595 597 10.1007/s00428-010-0924- 6 20422210
17. C. Bruns G. Weckbecker F. Raulf, et al. 1994 Molecular pharmacology of somatostatin-receptor subtypes Ann N Y Acad Sci 733 138 146 10.1111/j.1749-6632. 1994.tb17263.x 1:CAS:528:DyaK2MXjvFWrtb4%3D 7978861
18. P. Lambert A. Minghini W. Pincus, et al. 1996 Treatment and prognosis of primary malignant small bowel tumors Am Surg 62 709 715 1:STN:280: DyaK28zltVWmsg%3D%3D 8751760
19. Y.C. Patel 1997 Molecular pharmacology of somatostatin receptor subtypes J Endocrinol Invest 20 348 367 1:CAS:528:DyaK2sXmt1Ckur8%3D 9294784
20. W. Bauer U. Briner W. Doepfner, et al. 1982 SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action Life Sci 31 1133 1140 10.1016/0024-3205(82)90087-X 1:CAS:528:DyaL38XlslGhtLg%3D 6128648
21. Y.C. Patel 1999 Somatostatin and its receptor family Front Neuroendocrinol 20 157 198 10.1006/frne.1999.0183 1:CAS:528:DyaK1MXkvVOrsLc%3D 10433861
22. S.W. Lamberts A.J. van der Lely W.W. de Herder L.J. Hofland 1996 Octreotide N Engl J Med 334 246 254 10.1056/NEJM199601253340408 1:CAS:528:DyaK28Xhtl2rtrw%3D 8532003
23. R. Arnold B. Simon M. Wied 2000 Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review Digestion 62 [Suppl1] 84 91 10.1159/000051861 1:CAS:528:DC%2BD3cXmtVaku7s%3D 10940693
24. P. Grass P. Marbach C. Bruns I. Lancranjan 1996 Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: pharmacokinetic and pharmacodynamic relationships Metabolism 45 [Suppl1] 27 30 10.1016/S0026- 0495(96)90075-X 1:STN:280:DyaK28zlvVCntw%3D%3D 8769375
25. P. Caron A. Beckers D.R. Cullen, et al. 2002 Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly J Clin Endocrinol Metab 87 99 104 10.1210/jc.87.1.99 1:CAS:528:DC%2BD38XntVygtg%3D%3D 11788630
26. L.K. Kvols C.G. Moertel M.J. O'Connell, et al. 1986 Treatment of the malignant carcinoid syndrome Evaluation of a long-acting somatostatin analogue. N Engl J Med 315 663 666 1:STN:280:DyaL28zhtFSrsQ%3D%3D
27. E.T. Janson K. Oberg 1993 Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alphainterferon Acta Oncol 32 225 229 10.3109/02841869309083916 1:STN:280:DyaK3szht1GrtA%3D%3D 7686765
28. R. Arnold M.E. Trautmann W. Creutzfeldt, et al. 1996 Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours Gut 38 430 438 10.1136/gut.38.3.430 1:CAS:528:DyaK28XitlOjt7g%3D 8675099
29. L. Saltz B. Trochanowski M. Buckley, et al. 1993 Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors Cancer 72 244 248 10.1002/1097-0142(19930701)72:1<244:: AID-CNCR2820720143>3.0.CO;2-Q 1:STN:280:DyaK3s3osVGrsA%3D%3D 8389666
30. J. Garland J.R. Buscombe C. Bouvier, et al. 2003 Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience Aliment Pharmacol Ther 17 437 444 10.1046/j.1365-2036.2003.01420.x 1:CAS:528:DC%2BD3sXitlehtLs%3D 12562458
31. S. Faiss U. Räth U. Mansmann, et al. 1999 Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors Digestion 60 469 476 10.1159/000007693 1:CAS:528:DyaK1MXls1Klsrw%3D 10473972
32. P. Ruszniewski M. Ducreux J.A. Chayvialle, et al. 1996 Treatment of the carcinoid syndrome with the long-acting somatostatin analogue lanreotide: a prospective study in 39 patients Gut 39 279 283 10.1136/gut.39.2.279 1:CAS:528:DyaK28Xmt1eitLw%3D 8977344
33. A.N. Wymenga B. Eriksson P.I. Salmela, et al. 1999 Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms J Clin Oncol 17 1111 1:CAS:528: DyaK1MXisFentbo%3D 10561168
34. S. Ricci A. Antonuzzo L. Galli, et al. 2000 Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors Am J Clin Oncol 23 412 415 10.1097/00000421-200008000-00020 1:STN:280:DC%2BD3cvktFeitg%3D%3D 10955874
35. M. Ducreux P. Ruszniewski J.A. Chayvialle, et al. 2000 The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors J Gastroenterol 95 3276 3281 1:CAS:528:DC%2BD3cXos1ygsLg%3D
36. P. Ruszniewski S. Ish-Shalom M. Wymenga, et al. 2004 Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide Neuroendocrinology 80 244 251 10.1159/000082875 1:CAS:528:DC%2BD2MXmsVOgug%3D%3D 15627802
37. D. O'Toole M. Ducreux G. Bommelaer, et al. 2000 Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance Cancer 88 770 776 10.1002/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0 10679645
38. G. Vitale P.M. van Koetsveld W.W. de Herder, et al. 2009 Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells Am J Physiol Endocrinol Metab 296 E559 E566 10.1152/ajpendo.90770. 2008 1:CAS:528:DC%2BD1MXjtFGrtL8%3D 19141687
39. S. Pestka 1987 Advances in cancer: interferon - achievements and potential N J Med 84 1 51 56 1:STN:280:DyaL2s3gt1GhsA%3D%3D 3472107
40. S. Rosewicz K. Detjen A. Scholz Z. von Marschall 2004 Interferon-alpha: regulatory effects on cell cycle and angiogenesis Neuroendocrinology 80 [Suppl1] 85 93 10.1159/000080748 1:CAS:528:DC%2BD2cXotlahtbY%3D 15477724
41. L.J. Hofland W.W. de Herder M. Waaijers, et al. 1999 Interferon-alpha-2a is a potent inhibitor of hormone secretion by cultured human pituitary adenomas J Clin Endocrinol Metab 84 3336 3343 10.1210/jc.84.9.3336 1:CAS:528: DyaK1MXlvVGkt7k%3D 10487708
42. K. Oberg K. Funa G. Alm 1983 Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome N Engl J Med 309 129 133 1:STN:280:DyaL3s3ksVynsg%3D%3D 6191217
43. C.G. Moertel J. Rubin L.K. Kvols 1989 Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon J Clin Oncol 7 865 868 1:STN:280:DyaL1M3ptlWktQ%3D%3D 2738623
44. U. Plöckinger B. Wiedenmann 2007 Neuroendocrine tumors Biotherapy. Best Pract Res Clin Endocrinol Metab 21 145 162 10.1016/j.beem.2007.01.002
45. L. Kölby G. Persson S. Franzén B. Ahrén 2003 Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours Br J Surg 90 687 693 10.1002/bjs.4149 12808615
46. S. Faiss U.F. Pape M. Böhmig, et al. 2003 Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group J Clin Oncol 21 2689 2696 10.1200/JCO.2003.12.142 1:CAS:528:DC%2BD2cXptlCktLk%3D 12860945
47. R. Arnold A. Rinke K.J. Klose, et al. 2005 Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial Clin Gastroenterol Hepatol 3 761 771 10.1016/S1542-3565(05)00481-7 1:CAS:528:DC%2BD2MXhtVWjtLjF 16234004
48. N. Fazio F. de Braud G. Delle Fave K. Oberg 2007 Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination? Ann Oncol 18 13 19 10.1093/annonc/mdl144 1:STN:280:DC%2BD2s%2FisVWgsw%3D%3D 16798833
49. C.G. Moertel L.K. Kvols M.J. O'Connell J. Rubin 1991 Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms Cancer 68 227 232 10.1002/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0. CO;2-I 1:STN:280:DyaK3MzgtVCjuw%3D%3D 1712661
50. J.D. Hainsworth D.R. Spigel S. Litchy F.A. Greco 2006 Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study J Clin Oncol 24 3548 3554 10.1200/JCO.2005.05.0575 1:CAS:528:DC%2BD28XovVSjs7w%3D 16877720
51. E. Mitry E. Baudin M. Ducreux, et al. 1999 Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin Br J Cancer 81 1351 1355 10.1038/sj.bjc.6690325 1:CAS:528:DC%2BD3cXls1KksA%3D%3D 10604732
52. J.A. Chan M.H. Kulke 2009 Progress in the treatment of neuroendocrine tumors Curr Oncol Rep 11 193 199 10.1007/s11912-009-0028-0 19336011
53. P.F. Engstrom P.T. Lavin C.G. Moertel E. Folsch H.O. Douglass Jr 1984 Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor J Clin Oncol 2 1255 1259 1:STN:280:DyaL2M%2Fjt1yjtA%3D%3D 6238136
54. R.M. Bukowski C.M. Tangen R.F. Peterson, et al. 1994 Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study Cancer 73 1505 1508 10.1002/1097-0142(19940301) 73:5<1505::AID-CNCR2820730530>3.0.CO;2-V 1:STN:280:DyaK2c7lsFWgtw%3D%3D 8111718
55. S.M. Ansell H.C. Pitot P.A. Burch, et al. 2001 A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors Cancer 91 1543 1548 10.1002/1097-0142(20010415)91:8<1543::AID-CNCR1163>3.0.CO;2-N 1:CAS:528:DC%2BD3MXjt1Srsbg%3D 11301403
56. M.H. Kulke H. Kim K. Stuart, et al. 2004 A phase II study of docetaxel in patients with metastatic carcinoid tumors Cancer Invest 22 353 359 10.1081/CNV-200029058 1:CAS:528:DC%2BD2cXmvF2jurk%3D 15493355
57. M.H. Kulke H. Kim J.W. Clark, et al. 2004 A Phase II trial of gemcitabine for metastatic neuroendocrine tumors Cancer 101 934 939 10.1002/cncr.20466 1:CAS:528:DC%2BD2cXnvVGisro%3D 15329900
58. S.M. Ansell M.R. Mahoney E.M. Green J. Rubin 2004 Topotecan in patients with advanced neuroendocrine tumors: a phase II study with significant hematologic toxicity Am J Clin Oncol 27 232 235 10.1097/01.COC.0000054535.19808. F4 1:CAS:528:DC%2BD2cXlsFGgt7c%3D 15170140
59. S. Ekeblad A. Sundin E.T. Janson, et al. 2007 Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors Clin Cancer Res 13 2986 2991 10.1158/1078-0432.CCR-06-2053 1:CAS:528: DC%2BD2sXlt1Krtro%3D 17505000
60. Chan JA, Zhu AX, Stuart K et al (2010) Phase II study of pemetrexed in patients with advanced neuroendocrine tumors. Cancer Chemother Pharmacol [Epub ahead of print]
61. B. Basu B. Sirohi P. Corrie 2010 Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin Endocr Relat Cancer 17 R75 R90 10.1677/ERC-09-0108 1:CAS:528:DC%2BC3cXksVylu74%3D 20008097
62. C.G. Moertel J.A. Hanley L.A. Johnson 1980 Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma N Engl J Med 303 1189 1194 1:STN:280:DyaL3M%2FjtVOlug%3D%3D 6252466
63. C.G. Moertel M. Lefkopoulo S. Lipsitz, et al. 1992 Streptozocin- doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma N Engl J Med 326 519 523 1:STN:280: DyaK387itlejuw%3D%3D 1310159
64. P. Rougier J. Oliveira M. Ducreux, et al. 1991 Metastatic carcinoid and islet cell tumours of the pancreas: a phase II trial of the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin and cisplatin Eur J Cancer 27 1380 1382 10.1016/0277-5379(91)90014-5 1:STN:280: DyaK38%2FnsFeltw%3D%3D 1660291
65. E. Bajetta L. Rimassa C. Carnaghi, et al. 1998 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors Cancer 83 372 378 10.1002/(SICI)1097-0142(19980715)83:2<372::AID- CNCR23>3.0.CO;2-P 1:CAS:528:DyaK1cXkvVensrc%3D 9669822
66. Strosberg JR, Choi J, Gardner N, Kvols L (2008) First-line treatment of metastatic pancreatic endocrine carcinomas with capecitabine and temozolomide. J Clin Oncol 26:[Suppl] (Abstr 4612)
67. W. Sun S. Lipsitz P. Catalano, et al. 2005 Eastern Cooperative Oncology Group. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281 J Clin Oncol 23 4897 4904 10.1200/JCO.2005.03.616 1:CAS:528:DC%2BD2MXpsFWmt7c%3D 16051944
68. K. Oberg 2010 Cancer: antitumor effects of octreotide LAR, a somatostatin analog Nat Rev Endocrinol 6 188 189 10.1038/nrendo.2010.3 1:CAS:528: DC%2BC3cXjvVGnt78%3D 20336162
69. R.L. Adams I.P. Adams S.W. Lindow, et al. 2005 Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium Br J Cancer 92 1493 1498 10.1038/sj.bjc.6602503 1:CAS:528:DC%2BD2MXjsVSjsb8%3D 15812556
70. R. Mentlein O. Eichler F. Forstreuter J. Held-Feindt 2001 Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells Int J Cancer 92 545 550 10.1002/ijc.1223 1:CAS:528:DC%2BD3MXjs1eit7s%3D 11304689
71. D.E. Elliott J. Li A.M. Blum, et al. 1999 SSTR2A is the dominant somatostatin receptor subtype expressed by inflammatory cells, is widely expressed and directly regulates T cell IFN-gamma release Eur J Immunol 29 2454 2463 10.1002/(SICI)1521-4141(199908)29:08<2454::AID-IMMU2454>3.0.CO;2-H 1:CAS:528:DyaK1MXltFSlt70%3D 10458759
72. S.Q. Zhang W. Yang M.I. Kontaridis, et al. 2004 Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment Mol Cell 13 341 355 10.1016/S1097-2765(04)00050-4 14967142
73. A. Rinke H.H. Müller C. Schade-Brittinger, et al. 2009 Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group J Clin Oncol 27 4656 4663 10.1200/JCO.2009.22.8510 1:CAS:528:DC%2BD1MXhtlGgtbnJ 19704057
74. H.A. Schmid 2008 Pasireotide (SOM230): development, mechanism of action and potential applications Mol Cell Endocrinol 286 69 74 10.1016/j.mce.2007.09. 006 1:CAS:528:DC%2BD1cXmtVSmtbs%3D 17977644
75. H.A. Schmid P. Schoeffter 2004 Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors Neuroendocrinology 80 [Suppl1] 47 50 10.1159/000080741 1:CAS:528:DC%2BD2cXotlahtb8%3D 15477717
76. Kvols L, Öberg K, O'Dorisio TM et al (2010) Efficacy, safety and pharmacokinetic results from a phase ii study of pasireotide (SOM230) in the treatment of patients with metastatic NETs refractory or resistant to octreotide LAR. Presented at European Neuroendocrine Tumor Society (ENETS) Annual Conference, March 2010, Berlin, Germany
77. R. Srirajaskanthan J. Watkins L. Marelli, et al. 2009 Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies Neuroendocrinology 89 308 314 10.1159/000179899 1:CAS:528:DC%2BD1MXkvV2jsLw%3D 19307732
78. P. Jaquet G. Gunz A. Saveanu, et al. 2005 BIM- 23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide J Endocrinol Invest 28 [Suppl] 21 27 1:STN:280:DC%2BD283hvV2kug%3D%3D 16625841
79. E. Peverelli L. Olgiati M. Locatelli, et al. 2010 The dopamine-somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways Cancer Lett 288 170 176 10.1016/j.canlet.2009.06.034 1:CAS:528:DC%2BC3cXhtlSjurs%3D 19619936
80. J. Zhang Z. Jia Q. Li, et al. 2007 Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors Cancer 109 1478 1486 10.1002/cncr.22554 1:CAS:528:DC%2BD2sXlt1GmtL4%3D 17340592
81. J.C. Yao 2007 Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma Best Pract Res Clin Endocrinol Metab 21 163 172 10.1016/j.beem.2007.01.006 1:CAS:528:DC%2BD2sXjsVSqtrc%3D 17382271
82. E. Missiaglia I. Dalai S. Barbi, et al. 2010 Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway J Clin Oncol 28 245 255 10.1200/JCO.2008.21.5988 1:CAS:528:DC%2BC3cXjtVSqt7c%3D 19917848
83. J.C. Yao A. Phan P.M. Hoff, et al. 2008 Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b J Clin Oncol 26 1316 1323 10.1200/JCO.2007.13.6374 1:CAS:528:DC%2BD1cXksVehu7k%3D 18323556
84. Kunz PL, Kuo T, Kaiser HL et al (2008) A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors: preliminary results. J Clin Oncol 26[Suppl] (Abstr 15502)
85. Venook AP, Ko AH, Tempero MA et al (2008) Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors. J Clin Oncol 26[Suppl] (Abstr 15545)
86. J.G. Christensen 2007 A preclinical review of sunitinib, a multitageted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumor activities Ann Oncol 18 [Suppl10] 3 10 10.1093/annonc/mdm408
87. S. Faivre G. Demetri W. Sargent E. Raymond 2007 Molecular basis for sunitinib efficacy and future clinical development Nat Rev Drug Discov 6 734 745 10.1038/nrd2380 1:CAS:528:DC%2BD2sXpslaksL8%3D 17690708
88. E. Raymond S. Faivre P. Hammel P. Ruszniewski 2009 Sunitinib paves the way for targeted therapies in neuroendocrine tumors Target Oncol 4 253 254 10.1007/s11523-009-0130-0 19911111
89. S. Faivre C. Delbaldo K. Vera, et al. 2006 Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer J Clin Oncol 24 25 35 10.1200/JCO.2005.02. 2194 1:CAS:528:DC%2BD28Xot1ChtQ%3D%3D 16314617
90. M.H. Kulke H.J. Lenz N.J. Meropol, et al. 2008 Activity of sunitinib in patients with advanced neuroendocrine tumors J Clin Oncol 26 3403 3410 10.1200/JCO.2007.15.9020 1:CAS:528:DC%2BD1cXpvVWitro%3D 18612155
91. Raymond E, Niccoli-Sire P, Bang Y et al (2010) Updated results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of advanced pancreatic neuroendocrine tumors (NET). Paper presented at the 2010 gastrointestinal cancers symposium [Abstract 127]
92. Vinik A, Bang Y, Raoul J et al (2010) Patient-reported outcomes (PROs) in patients (pts) with pancreatic neuroendocrine tumors (NET) receiving sunitinib (SU) in a phase III trial. J Clin Oncol 28[Suppl] (Abstr 4003)
93. Raymond E, Niccoli P, Raoul J et al (2010) Cox proportional hazard analysis of sunitinib (SU) efficacy across subgroups of patients (pts) with progressive pancreatic neuroendocrine tumors (NET). J Clin Oncol 28[Suppl] (Abstr 4031)
94. D. Karhoff S. Sauer J. Schrader, et al. 2007 Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target Neuroendocrinology 85 45 53 10.1159/000100508 1:CAS:528:DC%2BD2sXjslOks78%3D 17341847
95. D. Strumberg H. Richly R.A. Hilger, et al. 2005 Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors J Clin Oncol 23 965 972 10.1200/JCO.2005.06.124 1:CAS:528: DC%2BD2MXit1Ggu7c%3D 15613696
96. T.J. Hobday J. Rubin K. Holen, et al. 2007 MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study J Clin Oncol 18 [Suppl] 4504
97. H.I. Hurwitz A. Dowlati S. Saini, et al. 2009 Phase I trial of pazopanib in patients with advanced cancer Clin Cancer Res 15 4220 4227 10.1158/1078-0432.CCR-08-2740 1:CAS:528:DC%2BD1MXntlOitr4%3D 19509175
98. C.N. Sternberg I.D. Davis J. Mardiak, et al. 2010 Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 1061 1068 10.1200/JCO.2009.23.9764 1:CAS:528: DC%2BC3cXktF2lt78%3D 20100962
99. Phan AT, Yao JC, Fogelman DR et al (2010) Pazopanib and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). J Clin Oncol 28[Suppl] (Abstr 4001)
100. K.D. Courtney R.B. Corcoran J.A. Engelman 2010 The PI3K pathway as drug target in human cancer J Clin Oncol 28 1075 1083 10.1200/JCO.2009.25.3641 1:CAS:528:DC%2BC3cXktF2lt7w%3D 20085938
101. I. Duran J. Kortmansky D. Singh, et al. 2006 A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas Br J Cancer 95 1148 1154 10.1038/sj.bjc.6603419 1:CAS:528:DC%2BD28XhtFChs7vP 17031397
102. S. Grozinsky-Glasberg G. Franchi M. Teng, et al. 2008 Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line Neuroendocrinology 87 168 181 10.1159/000111501 1:CAS:528:DC%2BD1cXkvVGrsrs%3D 18025810
103. J.C. Yao A.T. Phan D.Z. Chang, et al. 2008 Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study J Clin Oncol 26 4311 4318 10.1200/JCO.2008.16.7858 18779618
104. J.C. Yao C. Lombard-Bohas E. Baudin, et al. 2010 Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial J Clin Oncol 28 69 76 10.1200/JCO.2009.24.2669 1:CAS:528:DC%2BC3cXhtF2rsr4%3D 19933912
105. Yao JC, Phan AT, Fogleman D et al (2010) Randomized run-in study of bevacizumab (B) and everolimus (E) in low- to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker. J Clin Oncol 28[Suppl] (Abstr 4002)
106. M. Höpfner V. Baradari A. Huether, et al. 2006 The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours Endocr Relat Cancer 13 135 149 10.1677/erc.1.01090 16601284
107. Reidy DL, Hollywood E, Segal M, Saltz L (2010) Randomized run-in study of bevacizumab (B) and everolimus (E) in low- to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker. J Clin Oncol 28[Suppl] (Abstr 4163)
108. Rothenberg ML, Tolcher AW, Sarantopoulos J et al (2009) AMG 479 monotherapy to treat patients with advanced GI carcinoid tumors: A subset analysis from the first-in-human study. Paper presented at the 2009 gastrointestinal cancers symposium (Abstract 386)
109. Anthony LB, Loehrer PJ, Leong S et al (2010) Phase II study of cixutumumab (IMC-A12) plus depot octreotide for patients with metastatic carcinoid or islet cell carcinoma. J Clin Oncol 28[Suppl] (Abstr TPS220)
110. J.A. Gilbert R.V. Lloyd M.M. Ames 2005 Lack of mutations in EGFR in gastroenteropancreatic neuroendocrine tumors N Engl J Med 353 209 210 10.1056/NEJM200507143530219 1:CAS:528:DC%2BD2MXmtFGnsrc%3D 16014895
111. B. Zierhut K. Mechtler W. Gartner, et al. 2004 Heat shock protein 70 (Hsp70) subtype expression in neuroendocrine tissue and identification of a neuroendocrine tumour-specific Hsp70 truncation Endocr Relat Cancer 11 377 389 10.1677/erc.0.0110377 1:CAS:528:DC%2BD2cXlsl2msbY%3D 15163312
112. M. Shimakage K. Kodama K. Kawahara, et al. 2009 Downregulation of drs tumor suppressor gene in highly malignant human pulmonary neuroendocrine tumors Oncol Rep 21 1367 1372 10.3892/or-00000362 1:CAS:528:DC%2BD1MXmsVaqsb0%3D 19424611